Ibudilast and Interferon-beta Combination for Progressive Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for progressive multiple sclerosis lack efficacy and safety, particularly in the absence of overt inflammation, and there is a need for a convenient and effective treatment option that can slow disease progression without significant side effects.
Innovation Solution
A combination therapy involving a therapeutically effective amount of ibudilast and interferon-beta, administered separately or simultaneously, to alleviate symptoms and slow the progression of progressive multiple sclerosis, with options for varying dosages and administration schedules to enhance patient compliance and treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-beta is used as monotherapy for progressive multiple sclerosis, then some anti-inflammatory effect is achieved, but efficacy is insufficient and disease progression continues
Solution Approach 1:
The patent combines interferon-beta with ibudilast into a single therapeutic regimen. Interferon-beta provides immunomodulatory effects while ibudilast contributes neuroprotective and anti-inflammatory properties through PDE inhibition. This combination addresses both the inflammatory and neurodegenerative components of progressive MS, achieving synergistic disease modification that exceeds monotherapy efficacy.
Solution Approach 2:
The treatment approach uses a composite therapeutic strategy combining two distinct mechanisms of action. Interferon-beta (immunomodulator) and ibudilast (PDE inhibitor with neuroprotective properties) work together as complementary agents, similar to how composite materials combine different substances to achieve properties neither material possesses alone.
2Reliability
If mitoxantrone is used for secondary progressive multiple sclerosis, then disease progression is slowed, but serious side effects occur including heart injury and blood cancers
Solution Approach 1:
The patent employs ibudilast, a small molecule with a favorable safety profile and short half-life, as a safer alternative to mitoxantrone. Ibudilast can be administered orally with minimal accumulation and reversible effects, eliminating the need for long-term monitoring required with mitoxantrone's cardiotoxic and carcinogenic risks.
Solution Approach 2:
The invention transforms the therapeutic approach by using ibudilast's PDE inhibition mechanism to achieve neuroprotection without mitoxantrone's harmful effects. Ibudilast selectively inhibits PDE3, PDE4, and PDE10A to modulate cAMP and cGMP signaling pathways, providing disease modification through beneficial cellular mechanisms while avoiding mitochondrial toxicity and DNA damage.
3Ease of operation
If anti-inflammatory therapies are applied to progressive multiple sclerosis, then some symptomatic relief is achieved, but the therapies are not generally considered efficacious in the absence of overt inflammation
Solution Approach 1:
Ibudilast exhibits multiple mechanisms of action that address different pathological processes in progressive MS. It functions as a PDE inhibitor (affecting cAMP/cGMP signaling), an anti-inflammatory agent, and a neuroprotective compound. This multi-functionality allows the drug to be effective whether or not overt inflammation is present, bridging the gap between relapsing and progressive disease phases.
Solution Approach 2:
The invention changes the therapeutic parameter from purely anti-inflammatory (interferon-beta alone) to include neuroprotective signaling modulation through PDE inhibition. By targeting cAMP and cGMP pathways, ibudilast modifies cellular parameters such as neuronal survival signaling, axonal protection, and glial cell activation, providing efficacy independent of inflammatory markers.
Data Source
Figure 1
AI summary
This disclosure is directed to methods of alleviating the negative effects of, treating, or slowing the progression of progressive multiple sclerosis in human patients using ibudilast and interferon-beta.